Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
efficacy estimand)
Pathway context only, not a product effect
Phase II to Phase III fails without a program office already aware of the technology and with budget moving toward it
Purpose-built for physicians GLP-1s tied to lower risk for 10 types of cancer compared with insulin in type 2 diabetes Key takeaways: People with type 2 diabetes using a GLP-1 medication have a lower risk for most obesity-associated cancers than insulin users
Xarelto (rivaroxaban) Disease area(s): Cardiovascular/hematology Manufacturer(s): Bayer/Johnson & Johnson 2024 Sales (USD): $6.14 billion Why it sold so well: In 2024, Bayers Xarelto experienced a significant 7% decline in global revenues of Imbruvica due to the expiration of its patent protection, leading to increased generic competition
Choose a form that is convenient for you and easy to take
